Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBT (2020 - 2025)

Roivant Sciences (ROIV) has disclosed EBT for 6 consecutive years, with -$290.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 23.82% year-over-year to -$290.4 million, compared with a TTM value of -$953.2 million through Dec 2025, down 120.39%, and an annual FY2025 reading of -$681.6 million, down 114.92% over the prior year.
  • EBT was -$290.4 million for Q4 2025 at Roivant Sciences, down from -$159.0 million in the prior quarter.
  • Across five years, EBT topped out at $5.2 billion in Q4 2023 and bottomed at -$684.4 million in Q3 2021.
  • Average EBT over 5 years is $83.5 million, with a median of -$269.3 million recorded in 2025.
  • The sharpest move saw EBT tumbled 3248.44% in 2021, then surged 1448.82% in 2023.
  • Year by year, EBT stood at -$306.0 million in 2021, then dropped by 24.84% to -$382.1 million in 2022, then soared by 1448.82% to $5.2 billion in 2023, then crashed by 104.55% to -$234.5 million in 2024, then decreased by 23.82% to -$290.4 million in 2025.
  • Business Quant data shows EBT for ROIV at -$290.4 million in Q4 2025, -$159.0 million in Q3 2025, and -$269.3 million in Q2 2025.